

## References

S-60

1. CMS Online Manual Pub.100-3, National Coverage Determination (NCD) for Artificial Hearts and Related Devices. Section 20.9.
2. Califano S, Pagani F, Malani P. Left ventricular assist device-associated infections. *Infectious Disease Clinics of North America*. 2012; 26(1):77-87.
3. Sarker K, Kini A. Percutaneous left ventricular support device. *Cardiology Clinics*. 2010;28(1):169-184.
4. Weaver-Pinzon O, Stehlik J, Kfoury A, et al. Ventricular assist devices: Pharmacological aspects of a mechanical therapy. *Pharmacologic Therapy*. 2012;134(2):189-199.
5. Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Heart Failure Guidelines. American Heart Association. 2013 doi: 10.1161/CIR.0b013e31829e8776.
6. Fukamachi K, Shiose A, Massiello A, et al. Preload Sensitivity in Cardiac Assist Devices. *The Annals of Thoracic Surgery*. 2013;95(1):373-380.
7. PROTECT II: A prospective, multi-center, randomized controlled trial of the Impella Recover LP 2.5 System versus intra-aortic balloon pump (IABP) in patients undergoing non emergent high risk PCI. *Clinical trials.gov*.
8. Mukku VK, Cai Q, Gilani S, et al. Use of Impella ventricular assist device in patients with severe coronary artery disease presenting with cardiac arrest. *Int J Angiol*. 2012;21: 163-166.
9. O'Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. *Circulation*. 2012;126(14):1717-1727.
10. Schwartz BG, Ludemana DJ, Mayeda GS et al. Treating refractory cardiogenic shock with the TandemHeart and Impella devices: A single center experience. *Cardiol Res*. 2012;3(2):54-66.
11. Griffith B et al. The RECOVER I: A Multicenter Prospective Study of Impella 5.0/LD for Postcardiotomy Circulatory Support. *J Thorac Cardiovasc Surg*. 2013;145:548-554.
12. Lemaire A, Anderson MB, Prendergast T, et al. Outcome of the Impella Device for Acute Mechanical Circulatory Support. *Innovations*. 2013;8(1):12-16.
13. Dangas GD, Kini SK, Shama SK, et al. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). *Am J Cardiol*. 2014;113(2):222-228.
14. Henriques JP, Ouweneel DM, Naidu SS, et al. Evaluating the learning curve in the prospective randomized clinical trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon Pump in patients undergoing high-risk percutaneous coronary intervention: A prespecified subanalysis of the PROTECT II study. *Am Heart J*. 2014; 167:472-479.

15. Lemaire A, Anderson MB, Lee Ly, et al. The Impella Device for Acute Mechanical Circulatory Support in Patients in Cardiogenic Shock. *Annals Thor Surgery*. 2014; 97(1):133-138.
16. Maini B, Scotti DJ, Gregory D. Health economics of percutaneous hemodynamic support in the treatment of high-risk cardiac patients: A systematic appraisal of the literature. *Expert Rev*. 2014; 4: e1-14.
17. Impella® 2.5 with the automated Impella® Controller: Instructions for use & clinical reference manual. Abiomed®. Danvers, MA. 2013.
18. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction circulation; A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines.
19. Kovacic JC, Kini A, Banerjee S, et al. Patients with 3-vessel coronary artery disease and impaired ventricular function undergoing PCI with Impella 2.5 hemodynamic support have improved 90-day outcomes compared to intra-aortic balloon pump: a sub-study of the PROTECT II trial. *J Interv Cardiol*. 2015; 28(1):32-40.
20. Aryana A, Gearoid O'Neill P, Gregory D, et al. Procedural and clinical outcomes after catheter ablation of unstable ventricular tachycardia supported by a percutaneous left ventricular assist device. Abstract. *Heart Rhythm*. 2014; 11(7):1122-1130.
21. Demirozu ZT, Hernandez R, Mallidi HR, et al. HeartMate II left ventricular assist device implantation in patients with advanced hepatic dysfunction. *J Card Surg*. 2014; 29:419–423.
22. Reddy YM, Chinitz L, Mansour M, et al. Percutaneous left ventricular assist devices in ventricular tachycardia ablation: multicenter experience. *Circ Arrhythm Electrophysiol*. 2014; 7(2):244-250.
23. Cook JA, Shah KB, Quader MA, et al. The total artificial heart. *J Thorac Dis*. 2015;2172-2180.
24. Tsiouris A, Paone G, Nemeh HW, et al. Short and long term outcomes of 200 patients supported by continuous-flow left ventricular assist devices. *World J Cardiol*. 2015;792-800.
25. VanderPluym CJ, Fynn-Thompson F, Blume ED. Ventricular assist devices in children: Progress with an orphan device application. *Circulation*. 2014;1530-1537.
26. Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS Clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. AHA. 2015;7-26.
27. Peura JL, Colvin-Adams M, Francis GS, et al. Recommendations for the use of mechanical circulatory support: device strategies and patient selection a scientific statement from the American heart association. AHA. 2012;2648-2667.
28. Acharya D. Ventricular Assist Device in Acute Myocardial Infarction. *Journal of the American College of Cardiology*. 2016;67(16): 1781-1880.
29. Chen S. Outpatient Outcomes of Pediatric Patients with Left Ventricular Assist Devices. *American Society of Artificial Internal Organs*. 2016; 163-168.

30. Muthiah K. Longitudinal structural, functional, and cellular myocardial alterations with chronic centrifugal continuous-flow left ventricular assist device support. *The Journal of Heart and Lung Transplantation*. 2017;36(7): 722-731.
31. Rihal C. 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care. *Journal of the American College of Cardiology*. 2015;65(19): 1-20.